<DOC>
	<DOC>NCT00735761</DOC>
	<brief_summary>The purpose of this study is to evaluate the episode duration of a herpes labialis recurrence in immunocompromised patients treated with ME-609 or Acyclovir.</brief_summary>
	<brief_title>Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients</brief_title>
	<detailed_description>The objective of this study was to evaluate the episode duration of a herpes labialis recurrence, following a 5-day treatment with 5-time daily topical administration of ME-609 or acyclovir cream, in immunocompromised adults, 18 years and older. This interim report summarizes the results for short-term observations, i.e., during the initial study recurrence. A final study report will be prepared when the long-term follow-up is completed.</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>History of recurrent herpes labialis with at least two recurrences during the twelve months prior to the study. Stable HIV infection CD4+ Tcell count 100 to 500/mm3 Systemic treatment with other antiviral agent or corticosteroids within two weeks prior to and during the treatment period, except for antiretroviral treatment in HIV subjects Topical treatment with other antiviral agent or corticosteroids within in or around the oral area within two weeks prior to study drug administration Significant skin condition that occur in the area typically affected by herpes recurrences Nursing or pregnancy Concurrent cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>